Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 105B 68.26M 60.94M 55.92M 50.87M 95.37M 6.46B 97.27M 668M 269M 3.41B 256M 251M 10.77B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 336B 218M 195M 179M 162M 304M 20.63B 311M 2.13B 860M 10.89B 818M 800M 34.39B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
08-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-10 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
05-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
07/08/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/05/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
07/05/25 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
07/03/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
05/11/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
12/08/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
06/05/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
10/03/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+0.38%
1 week-3.33%
1 month-6.12%
3 months-15.81%
6 months-20.18%
Current year-33.92%
1 week 1,290
Extreme 1290
1,390
1 month 1,290
Extreme 1290
1,580
Current year 1,290
Extreme 1290
2,130
1 year 1,290
Extreme 1290
2,300
3 years 595.5
Extreme 595.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 28/04/2025
Corporate Officer/Principal - 28/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-3.33%-18.18%+94.78% 68.52M
-0.57%+10.19%+57.22%+142.90% 1,263B
-1.49%+1.07%+44.50%+79.15% 658B
-2.32%+0.50%+35.96%+101.16% 521B
-1.54%+0.18%+53.06%+66.79% 391B
-0.56%+5.53%+79.88%+44.27% 369B
-1.69%+3.17%+32.18%+55.35% 307B
-0.72%+7.83%+12.10%+33.76% 290B
-0.05%+4.75%+57.19%+74.70% 252B
-0.24%+7.01%+39.13%+109.05% 212B
Average -0.88%+5.19%+39.30%+80.19% 426.2B
Weighted average by Cap. -1.05%+6.60%+48.46%+92.99%

Financials

2024 2025
Net sales 91.79B 59.46M 53.08M 48.71M 44.31M 83.08M 5.63B 84.73M 582M 235M 2.97B 223M 218M 9.38B 127B 82.08M 73.28M 67.25M 61.17M 115M 7.77B 117M 803M 324M 4.1B 308M 301M 12.95B
Net income 23.85B 15.44M 13.79M 12.65M 11.51M 21.58M 1.46B 22.01M 151M 60.92M 772M 57.97M 56.73M 2.44B 3.09B 2M 1.79M 1.64M 1.49M 2.79M 189M 2.85M 19.57M 7.89M 99.94M 7.51M 7.35M 316M
Net Debt 134B 86.56M 77.28M 70.92M 64.51M 121M 8.2B 123M 847M 341M 4.33B 325M 318M 13.66B 231B 150M 134M 123M 112M 209M 14.17B 213M 1.46B 590M 7.48B 562M 550M 23.62B
Projected Income Statement - Annual - Laboratorios Richmond S.A.C.I.F.
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
30/10/26 ARS 1,305.00 +0.38% 693
29/10/26 ARS 1,300.00 -5.80% 982
28/10/26 ARS 1,380.00 +6.98% 784
27/10/26 ARS 1,290.00 -2.27% 993
26/10/26 ARS 1,320.00 -2.22% 407
  1. Stock Market
  2. Stocks
  3. RICH Stock